Actively Recruiting
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
Led by Eye & ENT Hospital of Fudan University · Updated on 2026-01-27
50
Participants Needed
1
Research Sites
242 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of induction chemotherapy combined with tislelizumab as neoadjuvant therapy in patients with locally advanced squamous cell carcinoma of the external auditory canal; to explore the improvement in the preservation rate of important neurovascular structures (including the facial nerve, internal carotid artery canal, sigmoid sinus, and posterior cranial nerves, etc.).
CONDITIONS
Official Title
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years and less than or equal to 80 years
- Pathological confirmation of squamous cell carcinoma
- Suitable for enhanced MRI or CT imaging assessment
- Previously untreated squamous cell carcinoma of the external auditory canal staged cT3-4NxM0 by Pittsburgh clinical staging
- Cases reviewed and approved by otologists
- Expected survival time of at least 1 year
- ECOG performance status score of 0 or 1
- Neutrophil count greater than 2,000/mm³ and platelet count greater than 100,000/mm³ before treatment
- Liver and kidney function tests within specified limits before treatment
- Signed informed consent form before study initiation
You will not qualify if you...
- Tumors not of squamous cell carcinoma type
- Early-stage disease (T1-T2) or distant metastasis (M1)
- Cases not reviewed with an otologist
- Previous radiotherapy for head and neck region
- Allergy to platinum-based or taxane drugs
- History of head and neck cancers or multiple primary tumors
- Positive pregnancy test in women of childbearing age
- Any other diseases or conditions affecting safe participation
- Active mental or psychological disorders impairing consent or understanding
- Uncontrolled active infections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Li Wang
Shanghai, Shanghai Municipality, China, 200031
Actively Recruiting
Research Team
C
Chunfu Dai
CONTACT
X
Xinmao Song
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here